RSV vaccine approved for use in at-risk over-50s The new TGA approval allows access to the Arexvy vaccine for at-risk adults aged 50–59, expanding the previous indication.
Longer pollen season bringing more risk for asthma patients Research shows the hay fever season is growing longer, and one expert says GPs are at the forefront of helping patients reduce complications.
Study examines whether RSV vaccine lasts ‘at least three winters’ The results of a randomised controlled trial indicate an RSV vaccine could offer protection against the virus over three seasons in over 60s.
General practice pilot to ease ‘significant impacts’ of hay fever To boost low adherence to treatments, a new trial aims to support GPs through a tailored education toolkit used alongside daily nasal spray.
First Arexvy safety data released The Australian-first safety data found 63% of recipients experienced no side effects in the first three days after vaccination.
Do GPs know enough about this ‘debilitating’ disorder? Experts agree there has been a dire lack of education around PMDD, but GPs could be in the ‘ideal situation’ to help.
Free RSV vaccination for Qld pregnant women Queensland’s expectant mothers are now eligible for a subsidised Abrysvo vaccination, as the state’s RSV cases soar to 40,000 in 2024.
RSV vaccine added to national program To ensure ‘every single infant in Australia is protected’, a $174.5 million investment will see free vaccines for pregnant people available nationwide.
Whooping cough epidemic reaches record numbers GPs are urged to ensure patients have had their vaccine, as ‘staggeringly high’ cases soar to a record-breaking 41,772 so far this year.
Victoria subsidises RSV immunisations for babies The State Government will fund the long-acting monoclonal antibody for unprotected newborns and eligible infants next winter.